Skip to main content Back to Top
Advertisement

5/8/2018

Ezetimibe and Atorvastatin Tablets

Products Affected - Description

    • Liptruzet tablet, Merck, 10 mg/ 10 mg, unit of use packages of 90, NDC 66582-0320-54
    • Liptruzet tablet, Merck, 10 mg/ 10 mg, unit of use packages of 30, NDC 66582-0320-30
    • Liptruzet tablet, Merck, 10 mg/ 20 mg, unit of use packages of 90, NDC 66582-0321-54
    • Liptruzet tablet, Merck, 10 mg/ 20 mg, unit of use packages of 30, NDC 66582-0321-30
    • Liptruzet tablet, Merck, 10 mg/ 40 mg, unit of use packages of 90, NDC 66582-0322-54
    • Liptruzet tablet, Merck, 10 mg/ 40 mg, unit of use packages of 30, NDC 66582-0322-30
    • Liptruzet tablet, Merck, 10 mg/ 80 mg, unit of use packages of 90, NDC 66582-0323-54
    • Liptruzet tablet, Merck, 10 mg/ 80 mg, unit of use packages of 30, NDC 66582-0323-30

Reason for the Shortage

    • In January 2014, Merck recalled all Liptruzet lots from wholesalers due to packaging defects in the outer laminate foil pouches.
    • Merck discontinued Liptruzet in June 2016.

Available Products

    • No products are available.

Estimated Resupply Dates

    • Merck discontinued all Liptruzet presentations in June 2015.

Updated

Updated May 8, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. Created February 24, 2014 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins